CVN424 is a non-dopamine therapy that inhibits G protein-coupled receptor 6 (GPR6), which is an orphan receptor as it has no naturally produced agonist that activates the receptor. The GPR6 inhibition can potentially improve motor and non-motor manifestations of Parkinson’s. The drug was discovered using Cerevance’s NETSseq (Nuclear Enriched Transcript Sort sequencing) platform.
Phase III trial for Cerevance’s lead CNS ... - Cure Parkinson's
Phase III trial for Cerevance’s lead CNS therapy, CVN424, in patients with Parkinson’s disease.
Written by
Farooqji
To view profiles and participate in discussions please or .
1 Reply
•
At this point in time, the Phase 2 trial for CVN424 (N=62) is still in progress, and still recruiting PwPs. It is scheduled to be completed in Feb 2025.
classic.clinicaltrials.gov/...
The purpose of the press release is to report that funding has been secured for a future Phase 3 trial.
Not what you're looking for?
You may also like...
Photopharmics kickstarts phototherapy trial for Parkinson’s disease
The US Food and Drug Administration (FDA)-approved device targets photoreceptors in the eye...
Tavapadon Lessens Motor Symptoms in Patients with Early-stage Parkinson’s, Phase 2 Trial Finds
https://parkinsonsnewstoday.com/2019/09/30/tavapadon-lessens-motor-symptoms-in-patients-with-early-s
MRI-Focused Ultrasound Undergoing Phase 3 Clinical Trial for Parkinson’s Treatment
New technology that uses MRI-guided focused ultrasound to target areas of the brain affected by...
Electroconvulsive Therapy Intervention for Parkinson’s Disease
Have not heard of this option before: Electroconvulsive Therapy Intervention for Parkinson’s...
Patient enrollment begins in study of novel light therapy for Parkinson’s disease
The first 100 patients have been enrolled in a clinical trial investigating a novel light therapy...
Related Posts
Gains seen in Parkinson’s with Symbyx’s red light therapy helmet
Bummer. Isradipine fails in Phase III Trial.- Randomized Trial of Focused Ultrasound Subthalamotomy for Parkinson’s Disease
Light Therapy for Parkinson’s Disease- Annovis Announces Unblinding of the Buntanetap Phase III Data in Parkinson’s Disease
